American Cancer Society to discuss the intricacies of cancer research

In the first few months of 2026, the news about advancements in cancer research including topics about targeted therapies, early detection and drug development. But to get a better idea of the “how,” “why” and “who decides,” it’s best to ask the experts. On March 11, Vail Symposium welcomes Dr. William Dahut, chief scientific officer of the American Cancer Society (ACS), and Steve Curtis, managing director of the venture capital arm of the ACS, to share the ins and outs of the research ecosystem.

“This is an incredible opportunity to understand a field that impacts every one of us and our loved ones,” said Vail Symposium executive director James Kenly. “The business of cancer research is complex, as is the science; understanding the space empowers us all to navigate it better.”

How does scientific research turn into cancer treatments? Who is doing the research and who is funding the research? What areas of cancer research are being funded and why? What is the government’s role in funding research and directing research policy and how does that impact the development of new treatments for cancer?

Dahut and Curtis will walk us through the research ecosystem including: governmental vs. non-governmental driven-research and funding; the process of translating research into treatments for patients; and the relationship between public policy and the impact in fighting cancer from prevention through survivorship.

Dahut is an internationally recognized physician-investigator, managing more than $400 million in research funding and guiding the American Cancer Society’s efforts to enhance and focus their research program, concentrate their priorities and working with key partners. He has authored nearly 250 publications in peer-reviewed journals and pioneered treatments in prostate and other cancers.

Support Local Journalism

Donate

Curtis is the interim managing director of BrightEdge and VP, Innovation and Impact Investing for American Cancer Society. Prior to ACS, Steve managed MPM Capital’s Oncology Innovations Fund, a hybrid venture/philanthropy investment collaboration with Dana-Farber Cancer Institute. He also has experience with Eli Lilly and Co., Bioscience Ventures group within 2M Cos., and Reata Pharmaceuticals.